Shaun J Kilty
Overview
Explore the profile of Shaun J Kilty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kilty S, Lasso A
J Otolaryngol Head Neck Surg
. 2024 Sep;
53:19160216241278659.
PMID: 39345032
Background: Dupilumab, an anti-IL4 receptor-α monoclonal antibody, was the first biologic to be approved in Canada for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). In phase III clinical...
2.
Yong M, Kirubalingam K, Desrosiers M, Kilty S, Thamboo A
Allergy Asthma Clin Immunol
. 2023 Oct;
19(1):90.
PMID: 37838713
Background: Dupilumab, omalizumab, and mepolizumab are the three biologics currently approved for use in CRSwNP in Canada. Despite evidence of efficacy, their cost-effectiveness, which is a key factor influencing prescribing...
3.
Caulley L, Whelan J, Khoury M, Mavedatnia D, Sahlollbey N, Amrani L, et al.
Pituitary
. 2022 Nov;
26(1):73-93.
PMID: 36422846
Context: Pituitary tumors are the third most common brain tumor and yet there is no standardization of the surveillance schedule and assessment modalities after transsphenoidal surgery. Evidence Acquisition: OVID, EMBASE...
4.
Caulley L, Krijkamp E, Doyle M, Thavorn K, AlKherayf F, Sahlollbey N, et al.
Pituitary
. 2022 Aug;
25(6):868-881.
PMID: 36030360
Purpose: The objective of this study was to compare the cost-effectiveness of preoperative octreotide therapy followed by surgery versus the standard treatment modality for growth-hormone secreting pituitary adenomas, direct surgery...
5.
Kilty S, Lasso A
J Otolaryngol Head Neck Surg
. 2022 Apr;
51(1):17.
PMID: 35468866
Background: Dupilumab is the first monoclonal antibody therapy to be approved in Canada for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The goal of the study was to...
6.
Kumar S, Thavorn K, van Katwyk S, Lasso A, Kilty S
Clin Otolaryngol
. 2020 Apr;
45(4):477-485.
PMID: 32227591
Objective: To compare costs and quality-adjusted life years of patients receiving endoscopic polypectomy in the clinic those receiving endoscopic sinus surgery from the perspective of Canada's health system. Method: We...
7.
Nithianandan H, Thavorn K, Banaz F, MacDonald K, Lasso A, Kilty S
World J Otorhinolaryngol Head Neck Surg
. 2020 Feb;
5(4):193-199.
PMID: 32083246
Objective: To estimate the hospital costs of managing anterior epistaxis in the Emergency Department at a Tertiary Care centre in Canada. Material And Methods: A cost analysis was conducted based...
8.
Lee J, Wu V, Faughnan M, Lasso A, Figol A, Kilty S
J Otolaryngol Head Neck Surg
. 2019 Oct;
48(1):48.
PMID: 31615556
Background: Epistaxis is the most common symptom of hereditary hemorrhagic telangiectasia (HHT), affecting more than 98% of adults with HHT, with significant impact on quality of life. Floseal® has been...
9.
Radonjic A, Moldovan I, Kilty S, Schramm D, AlKherayf F
Am J Case Rep
. 2019 Mar;
20:335-339.
PMID: 30867405
BACKGROUND Cholesterol granulomas of the petrous apex may impinge surrounding cranial nerves, leading to neurological impairments such as hearing loss. Less invasive endoscopic techniques are gaining popularity as the mainstay...
10.
Masoudian P, McDonald J, Lasso A, Kilty S
World J Otorhinolaryngol Head Neck Surg
. 2018 Dec;
4(4):263-267.
PMID: 30564789
Objective: Little was known about the role of socioeconomic status as a risk factor for epistaxis in adult population. The objective of this study was to determine whether socioeconomic status...